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In Brief Weon et al. show that MAGE-F1 specifies the cytosolic iron-sulfur assembly (CIA) pathway protein MMS19 for ubiquitination and degradation. MAGE-F1 is amplified in lung cancers, where it promotes tumor growth and increased mutational burden. These studies provide evidence for alteration of the CIA pathway in cancer through post-translational regulation.
INTRODUCTION
Iron-sulfur (Fe-S) clusters are one of the most ancient inorganic cofactors utilized by proteins from bacteria to humans (Lill, 2009 ). Generation of Fe-S, typically in the form of [2Fe-2S] or [4Fe-4S] (Rouault, 2015) , requires the coordinated activity of members of the mitochondrial iron-sulfur cluster assembly (ISC) machinery for mitochondrial Fe-S proteins or both the ISC and the cytosolic iron-sulfur cluster assembly (CIA) machinery for cytoplasmic and nuclear Fe-S proteins (Netz et al., 2014) . The CIA pathway, consisting of at least 9 components in humans , serves as a conduit by which iron-and sulfur-containing cofactors are generated from a precursor product of the mitochondria ISC and passed through a series of proteins to ultimately be incorporated into cytosolic or nuclear proteins that require the Fe-S cluster as a structural (Stehling et al., 2008 (Stehling et al., , 2012 , enzymatic (Beinert, 2000) , or electron transfer component (Rouault, 2015) . One of the critical end-target-binding adaptors for this process is MMS19, which binds a number of proteins, including those important for DNA repair processes, such as FANCJ, POLD1, XPD, and RTEL1, among others (Gari et al., 2012; Stehling et al., 2012 Stehling et al., , 2013 . Characterization of the loss of MMS19 has been well documented in yeast and more recently in human cells as displaying greater susceptibility to DNA-damaging agents (Gari et al., 2012; Lauder et al., 1996; Prakash and Prakash, 1979; Stehling et al., 2012) . Although new discoveries in the CIA pathway have focused on identifying the core assembly proteins, binding modalities of members of the pathway, and the specific Fe-S proteins targeted, there remains a large gap in understanding how the CIA pathway is regulated and altered in disease.
Here, we report that an E3 ubiquitin ligase in the MAGE-RING ligase (MRL) family controls flux through the CIA pathway through ubiquitination and degradation of MMS19. MRLs are a family of E3 ubiquitin ligases that consist of a complex between an E3 RING ubiquitin ligase and a modulatory MAGE protein, which can function to specify substrates for the ligase (Doyle et al., 2010; Hao et al., 2013 Hao et al., , 2015 Lee and Potts, 2017; . There are >40 MAGE proteins in humans, each containing a MAGE homology domain (MHD) that mediates binding to distinct E3 ubiquitin ligases (Doyle et al., 2010; Weon and Potts, 2015) . The specific cellular function of the majority of MAGE proteins, including MAGE-F1, has not been elucidated. In this study, we identify a function for the orphan MAGE-F1 in specifying MMS19 for ubiquitination and degradation by the NSE1 E3 ubiquitin ligase. This results in decreased Fe-S cluster assembly into MMS19 targets that functionally renders cells less competent to repair a spectrum of DNA damage. Interestingly, MAGE-F1 is copy-number amplified in several types of cancers, resulting in increased mutation burden in tumors, suggesting downregulation of the CIA pathway may be an important event in tumorigenesis. Figure 1B ). In addition, in vitro binding assays revealed that bacterially purified glutathione S-transferase (GST)-NSE1 directly binds MYC-MAGE-F1 ( Figure 1C) . A conserved dileucine motif has been identified in the MHD of most MAGEs and is critical for interaction with their cognate E3 ligases (Doyle et al., 2010) . Mutation of this motif in MAGE-F1 (L87-88A) abolished binding of MAGE-F1 to NSE1 ( Figure 1C ). NSE1 has previously been shown to interact with a closely related MAGE protein, MAGE-G1 (Taylor et al., 2008) . The MAGE-G1-NSE1 MRL incorporates into the SMC5/6 complex to facilitate homologous recombination (HR) between sister chromatids and telomeres (Potts, 2009; Potts et al., 2006; Potts and Yu, 2007) . Thus, we examined whether MAGE-F1 could simply replace MAGE-G1 in the SMC5/6 complex. However, MAGE-F1, unlike MAGE-G1, failed to interact with co-expressed or endogenous SMC5 or SMC6 ( Figures 1D and 1E ). Together, these results suggest that MAGE-F1 forms a complex with the NSE1 ubiquitin ligase but does not integrate into the SMC5/6 complex like MAGE-G1-NSE1. Consistent with this, it has been observed that a fraction of cellular NSE1 exists outside the SMC5/6 complex (Taylor et al., 2008) . Thus, the function of an E3 ligase (NSE1 in this case) can be diversified by association with different MAGE proteins. the MAGE-F1 interactome (Table S1 ) revealed three high-confidence substrates (MMS19, MAT2a, and PPM1G) that we confirmed bind to and are ubiquitinated by MAGE-F1-NSE1 (Figures 2A and S1A-S1D). Of these three substrates, MAGE-F1-NSE1 bound to and ubiquitinated MMS19 most robustly (Figures 2A and S1B-S1D). MMS19 ubiquitination was unaffected by MAGE-G1 expression (Figure 2A ). MAGE-F1 most robustly ubiquitinated the C-terminal domain (amino acids 857-1,030) of MMS19 ( Figure S1E ), which contains a cluster of five lysine residues (K993, K1002, K1007, K1008, and K1013). Mutation of these lysines to arginine (referred to herein as 5KR mutant) significantly blocked MMS19 ubiquitination by MAGE-F1 ( Figure 2B ). Furthermore, MAGE-F1 L87-88A mutant incapable of binding NSE1 failed to induce MMS19 ubiquitination ( Figure 2C ). Knockdown of NSE1 severely diminished MAGE-F1's ability to promote MMS19 ubiquitination ( Figure 2D ). These results suggest that MAGE-F1 in conjunction with NSE1 promotes MMS19 ubiquitination. Consistent with this, MMS19 bound recombinant His-MAGE-F1-NSE1 complex in vitro, but not His-NSE1 alone ( Figure 2E ).
NSE1 (

MAGE-F1-NSE1 MRL
Ubiquitination of MMS19 by MAGE-F1-NSE1 resulted in its degradation as knockdown of MAGE-F1 ( Figure S1F ) or NSE1 increased MMS19 protein levels ( Figure 2F ) without affecting MMS19 mRNA levels ( Figure 2G ). In contrast, expression of wild-type, but not MAGE-F1 L87-88A mutant, reduced endogenous MMS19 protein levels ( Figure 2H ). Importantly, downregulation of MMS19 by MAGE-F1 could be rescued by the proteasome inhibitor MG132 ( Figure 2H ). Additionally, knockout of MAGE-F1 in HeLa cells significantly increased MMS19 protein half-life ( Figure 2I ). Consistent with these findings, using ubiquitin Lys to Arg mutants that disrupt specific chain linkage types, we found that mutation of K48, but not K6, (A) HA-MAGE-F1, but not HA-MAGE-G1, robustly increases ubiquitination of MMS19. HeLa cells were transfected with the indicated constructs for 48 hr and treated with 10 mM MG132 for 4 hr followed by anti-MYC IP to pull-down ubiquitinated proteins followed by SDS-PAGE and immunoblotting for FLAG-MMS19. (B) Mutation of five lysines in the C terminus of MMS19 (K993, K1002, K1007, K1008, and K1013; 5KR) disrupts MAGE-F1-induced ubiquitination. Cells were treated and lysates were prepared as noted in (A). (C) Wild-type MAGE-F1, but not NSE1 binding defective mutant MAGE-F1 L87-88A (LA), induces ubiquitination of MMS19. Cells were treated and lysates were prepared as noted in (A).
(legend continued on next page) K11, K27, K29, K33, or K63, of ubiquitin impaired MAGE-F1-induced MMS19 ubiquitination in cells ( Figure 2J ). Finally, the MMS19 5KR mutant that fails to be robustly ubiquitinated by MAGE-F1 was resistant to MAGE-F1-induced degradation (Figures 3D and 4D, insets) . These results suggest that MAGE-F1 specifies MMS19 for ubiquitination by NSE1, leading to its degradation.
MAGE-F1-NSE1 MRL Decreases Iron Incorporation into MMS19 Targets MMS19, in conjunction with CIA1 and CIA2B, acts late in the CIA pathway to recruit apoproteins to the CIA machinery (namely IOP1/Nar1) for incorporation of the Fe-S cluster to form functional holoproteins (Gari et al., 2012; Lill et al., 2015; Seki et al., 2013; Stehling et al., 2012 Stehling et al., , 2013 van Wietmarschen et al., 2012) . In order to directly determine whether MAGE-F1-NSE1-mediated ubiquitination and degradation of MMS19 has an effect on CIA pathway flux and incorporation of Fe-S cluster into downstream targets, we labeled cells with 55 Fe, immunoprecipitated specific Fe-S proteins, and quantitated the amount of radioactivity present via scintillation counting, as has been previously described (Stehling et al., 2004; Teichmann and Stremmel, 1990) . We found that expression of MAGE-F1 decreased Fe-S cluster incorporation into downstream MMS19-dependent targets POLD1, FANCJ, XPD, DPYD, and RTEL1 to a similar extent as MMS19 knockdown by small interfering RNAs (siRNAs) (Figure 3A) . Importantly, MAGE-F1 did not affect 55 Fe incorporation into a MMS19-independent Fe-S protein, PPAT ( Figure 3A) , suggesting MAGE-F1 specifically modulates the MMS19 arm of the CIA pathway. Changes in 55 Fe incorporation upon MAGE-F1 expression were not due to altered 55 Fe cellular uptake or unequal immunoprecipitation of proteins (Figures S2A and S2B) . Consistent with MAGE-F1 affecting the MMS19 CIA pathway in conjunction with NSE1, knockdown of NSE1 abrogated the effects of MAGE-F1 expression on 55 Fe incorporation into FANCJ ( Figure 3B ). Furthermore, MAGE-F1 L87-88A that fails to bind NSE1 was incompetent to alter 55 Fe incorporation into FANCJ and XPD ( Figure 3C ). In contrast to MAGE-F1, no significant changes were found with 55 Fe incorporation into targets upon expression of MAGE-G1, again suggesting distinct functions of MAGE-G1-NSE1 and MAGE-F1-NSE1 ( Figure S2C ). Importantly, rescuing MMS19 protein levels in MAGE-F1-expressing cells by expressing the MMS19 5KR mutant returned CIA pathway activity to normal ( Figure 3D ). These effects of MAGE-F1 are not restricted to overexpression as knockout of MAGE-F1 increased levels of 55 Fe incorporation into FANCJ, POLD1, DPYD, and RTEL1 ( Figure 3E ). It has previously been shown that knockdown of MMS19 destabilizes a number of downstream target proteins due to their reliance on the Fe-S cluster for stability (Gari et al., 2012; Stehling et al., 2012) . Similarly to these findings, MAGE-F1 expression decreased FANCJ levels and to a smaller extent XPD, POLD1, and DPYD ( Figures  3F and 3G ). Rescuing MMS19 proteins levels in MAGE-F1-expressing cells returned FANCJ levels to baseline ( Figure 3H ).
Consistent with MAGE-F1-NSE1 abrogating MMS19 function, we also observed defects in iron homeostasis previously reported upon knockdown of MMS19 (Stehling et al., 2013) . Specifically, knockdown of MMS19 by siRNAs or expression of MAGE-F1 in HeLa cells showed robust increases in uptake of fluorescein isothiocyanate (FITC)-labeled transferrin (Figure S2D ). In contrast, knockout of MAGE-F1 decreased transferrin uptake, which could be rescued by re-expression of MAGE-F1 ( Figure S2E ). These results suggest that MAGE-F1-NSE1 ubiquitination and degradation of MMS19 impairs MMS19 functions, including flux through the CIA pathway and regulation of iron homeostasis.
MAGE-F1 Inhibits Homologous Recombination and Sensitizes Cells to DNA-Damaging Agents
Because MAGE-F1-mediated degradation of MMS19 leads to decreased incorporation of 55 Fe into several DNA repair enzymes, we examined whether this would alter cellular DNA repair mechanisms. To test this hypothesis, we utilized a previously described homologous recombination assay (Porteus and Baltimore, 2003; Potts et al., 2006) , in which a non-functional GFP containing in-frame stop codons can be repaired upon induction of a double-strand break by the I-SceI endonuclease and recombination with an episomal repair template ( Figure S3A ). We found that dose-dependent expression of wild-type MAGE-F1, but not MAGE-F1 L87-88A, reduced homologous recombination rates (Figures 4A, 4B, and S3B) . Similarly, knockdown of MMS19 in a dose-dependent manner phenocopied MAGE-F1 expression, resulting in decreased rates of homologous recombination (Figures 4C and S3C) . Importantly, MAGE-F1-induced reduction in homologous recombination was reversed upon rescuing MMS19 protein levels by expression of the non-ubiquitinatable MMS19 5KR mutant ( Figure 4D ). In order to determine what particular downstream MMS19 target(s) may be mediating its (D) MAGE-F1-induced ubiquitination of MMS19 depends on the NSE1 ligase. Cells were transfected with the indicated siRNAs (siControl or siNSE1) and plasmids for 72 hr and treated with 10 mM MG132 for 4 hr followed by anti-MYC IP to pull-down ubiquitinated proteins followed by SDS-PAGE and immunoblotting for MMS19. (E) MYC-MMS19 binds bacterially purified recombinant His-MAGE-F1-NSE1 complex, but not His-NSE1 alone, in vitro. Figure S3 .
effect on homologous recombination, we measured homologous recombination rates in cells depleted of several MMS19 targets affecting DNA metabolism, including FANCJ, POLD1, RTEL1, and XPD ( Figure 4E ). Consistent with previous reports demonstrating that FANCJ and POLD1 play important roles in homologous recombination (Litman et al., 2005; Maloisel et al., 2008) , knockdown of either, but not XPD or RTEL1, reduced homologous recombination rates similarly to MMS19 knockdown or MAGE-F1 expression ( Figure 4E ). Previous studies have also shown that depletion of MMS19 results in increased sensitivity to DNA-damaging agents (Lauder et al., 1996; Seki et al., 2013; Stehling et al., 2012) . Consistent with MAGE-F1 inhibition of the MMS19 pathway, stable expression of MAGE-F1 reduced cellular viability upon exposure to methyl methanesulfonate (MMS) ( Figure 4F ) and knockout of MAGE-F1 reduced sensitivity to both MMS and UV ( Figures 4G and 4H ) without affecting the cell cycle ( Figures S3D and S3E ). These results suggest that downregulation of MMS19 CIA pathway by MAGE-F1-NSE1 reduces the DNA repair capacity of cells.
Adaptive Pseudogenization of MAGE-F1 in Specific Mammalian Lineages
In the process of evaluating the function of MAGE-F1-NSE1 MRL in the mouse, we unanticipatedly found that the MAGE-F1 gene in mouse has a single-nucleotide frameshifting deletion leading to an in-frame stop codon that we confirmed by Sanger sequencing ( Figure S4 ). Like the majority of other MAGE genes, MAGE-F1 is only conserved in placental mammals (De Donato et al., 2017; Katsura and Satta, 2011; Zhao et al., 2012) . Surprisingly, we found that a large subset of mammals has a non-coding MAGE-F1 gene due to insertions, deletions, or mutations that lead to in-frame stop codons ( Figure 5A ). Pseudogenization of the MAGE-F1 gene has apparently happened multiple times, as several different mammalian lineages have mutations (Figure 5A) , with some specific hotspots for mutations in MAGE-F1 gene ( Figure 5B ). Genes that acquire mutations leading to noncoding RNAs often acquire additional mutations, given the relaxation on evolutionary pressure to keep the protein-coding gene intact. As a result, these pseudogenized genes build up mutations and the ratio of non-synonymous (dN) to synonymous (dS) mutations increases toward neutral evolution. Consistent with pseudogenization of MAGE-F1, we find multiple insertions, deletions, or mutations that lead to in-frame stops across most non-coding MAGE-F1 genes ( Figure 5A ). Furthermore, evaluating rates of dN and dS in MAGE-F1 from 60 mammals revealed a significant (p = 2.4 3 10 À14 ) increase in the dN/dS ratio in mammals with MAGE-F1 pseudogene ( Figure 5C ). Thus, MAGE-F1 has undergone adaptive pseudogenization in specific mammalian lineages to possibly alter MSM19 and CIA pathway function. Figures  6B and S5B ). Of note, amplification of MAGE-F1 does not happen in isolation and likely cooperates with other oncogenic drivers, as it is co-amplified with other known oncogenes on chr 3q, including PIK3CA, SOX2, and TP63 ( Figure S5C ). Given our findings that MAGE-F1 specifies downregulation of the MMS19 CIA pathway and reduces DNA repair capacity of cells, we examined whether tumors that harbor high amplification of MAGE-F1 exhibit greater genomic instability. Indeed, lung squamous cell carcinoma patient tumors with high levels of MAGE-F1 amplification and mRNA harbored a greater number of mutations per tumor ( Figures 6C, 6D , and S5D), with a wide spectrum of mutations as would be consistent with modulation of a large number of DNA enzymes that function in multiple pathways ( Figure 6E ). Importantly, high expression of other MAGEs, such as MAGE-A3, did not alter tumor mutation burden (Figure S5E ) and the effects of MAGE-F1 on mutational burden was not driven by difference in exposure to smoke-related carcinogens ( Figure S5F ). We similarly found increased total mutational burden in MAGE-F1-amplified head and neck squamous cell carcinomas as compared to non-MAGE-F1-amplified cases ( Figures  6F, 6G , and S5G). These results are likely clinically significant, as MAGE-F1 amplification, NSE1 expression levels, and the combination all showed robust decreases in survival of head and neck squamous carcinoma patients ( Figures 6H, S5H , and S5I).
To experimentally determine whether MAGE-F1 overexpression is both necessary and sufficient to drive tumor growth, we manipulated MAGE-F1 levels in lung squamous carcinoma cell lines and measured their xenograft tumor growth properties in mice. We identified two lung squamous carcinoma cell lines with naturally occurring copy number amplification and overexpression of MAGE-F1, HCC95, and H520. Strikingly, knockdown of MAGE-F1 in both HCC95 and H520 slowed xenograft tumor growth in mice ( Figures 6I, 6J , and S5J). To further test the sufficiency of MAGE-F1 to drive tumor growth, we expressed MAGE-F1 in a H2170 lung squamous carcinoma cell line that normally does not have copy number amplification of and overexpression of MAGE-F1 ( Figure S5K ). Using this model for MAGE-F1 amplification in lung squamous tumors, we measured xenograft growth rates in mice. In contrast to MAGE-F1 knockdown, overexpression of MAGE-F1 drove increased tumor xenograft tumor growth in mice ( Figure 6K ). These results suggest that MAGE-F1 copy number amplification and overexpression significantly contribute to tumorigenesis.
DISCUSSION
In summary, our results define a function for the orphan MAGE-F1 protein, provide evidence for diversification of E3 ligase function by MAGE proteins, and more importantly illustrate how post-translational regulation of the CIA Fe-S pathway can be achieved through ubiquitination and degradation of MMS19. These findings have a number of implications, including establishing a role for alteration of the CIA pathway in cancer and genomic stability.
MAGE-Dependent Switching of E3 Ligase Function
MAGEs bind to E3 ubiquitin ligases through their MHD (Doyle et al., 2010) . The specific sequence and conformational dynamics likely dictate which specific E3 RING ligase a given MAGE will bind. We and others have reported previously that similar MAGEs can, in some cases, bind to the same RING protein, such as MAGE-A3 and MAGE-A6 binding TRIM28 (Doyle et al., 2010; Yang et al., 2007) . However, in those cases, the MAGE proteins are very similar and have redundant activity. We describe here a case where two MAGEs, MAGE-F1 and MAGE-G1, can bind the same NSE1 RING protein but have non-overlapping functions. Mechanistically, how may the binding of two different MAGEs switch the function of an E3 RING ligase? One possibility is that the regions outside of the MHD in the N or C terminus may differ enough to bind different substrates and expand the substrate repertoire for NSE1. Alternatively, the binding of MAGE-F1 and MAGE-G1 may exert differential conformations on NSE1 that may promote different activities. Additionally, other binding partners may hinder interaction with substrates, such as binding of MAGE-G1-NSE1 to the SMC5/6 complex, which may hinder interaction with MMS19. Another possibility is that the different pools of MAGE-G1-NSE1 and MAGE-F1-NSE1 localize to distinct subcellular compartments. Regardless of the mechanism, diversification of E3 ligase function by MAGEs expands the regulatory potential of these proteins and allows contextual changes in multiple pathways through altering formation of distinct MRLs. In the case of NSE1, differential binding of MAGE-G1 and MAGE-F1 not only diversifies function but also promotes opposing activities, with MAGE-G1-NSE1 promoting DNA repair through SMC5/6 complex and MAGE-F1-NSE1 inhibiting DNA repair through degradation of MMS19.
Context-Dependent Regulation of Flux through the CIA Pathway
Under what specific contexts may cells (or organisms) need to regulate MMS19 and the CIA pathway? Insufficient cellular iron content may be one setting in which it would be beneficial to decrease the production of MMS19. In the case of E. coli, when iron becomes limiting, the bacterium reduces the transcript levels of highly expressed Fe-S proteins (Imlay, 2006) . Experiments from yeast demonstrated that limiting available iron using the cell-membrane-impermeable ferrous (Fe 2+ ) iron chelator bathophenanthroline disulfonate caused a robust decrease in MMS19 protein levels (Lev et al., 2013) . This decrease could be rescued by addition of the MG132 proteasome inhibitor, suggesting that MMS19 is post-translationally regulated in the context of low iron availability in yeast (Lev et al., 2013) . Alternatively, acute insults to DNA by carcinogens or the environment may necessitate the further stabilization of MMS19 levels to support the repair of widespread DNA damage. Consistent with this, MMS19 protein levels have been shown to be increased after UV damage (Ito et al., 2010) . In addition, it is important to consider that regulation of MMS19 alters not only production of DNA repair enzymes but also iron uptake by the transferrin receptor. Thus, regulation of MMS19 allows cells (and organisms) to balance iron uptake and DNA repair capacity. One setting in which generation of DNA repair machinery components may be inhibited in favor of iron uptake is when host defense against pathogens is necessary. Many bacteria and viruses require iron to proliferate, and thus, a key host-defense mechanism is to sequester iron away from pathogen access (Ganz and Nemeth, 2015) . Normally, upon infection, iron is sequestered by preventing cellular iron export, sequestration of plasma iron into proteins, and import of iron into cells (Ganz and Nemeth, 2015) . Import of iron into cells away from extracellular pathogens can occur in part through uptake of iron from transferrin through the transferrin receptor, which is impacted by MMS19 (Soares and Weiss, 2015) . Indeed, rats treated with lipopolysaccharide (LPS) to promote an immune response were found to have increased transferrin receptor mRNA and protein levels in the lung (Upton et al., 2003) . The importance of this defense mechanism is highlighted by the high pathogen susceptibility of patients with hereditary hemochromatosis, characterized by systemic iron overload due to mutations in various genes required to regulate iron homeostasis, including TFR2 (Johnson and Wessling-Resnick, 2012) . Therefore, in the setting of extracellular infection, it may be beneficial for cells to upregulate the transferrin receptor via downregulation of MMS19.
The CIA Pathway, MAGE-F1, and Smoking-Induced Cancers Many of the cancers in which MAGE-F1 is amplified are frequently associated with smoking: lung squamous cell carcinoma, esophageal carcinoma (Cook et al., 2010) , and head and neck squamous cell carcinoma (Mashberg et al., 1993) . Lesions caused by smoking include bulky adduct formation on purines, such as 8-oxo-guanine, which may be repaired through nucleotide excision repair pathways (Pleasance et al., 2010a) . It has been observed that, indeed, there are more unrepaired lesions in cancers caused by smoking (Alexandrov et al., 2013; Martincorena and Campbell, 2015; Pleasance et al., 2010b) . MMS19 was initially identified as a gene important for both global nucleotide excision repair and transcription-coupled repair. Thus, MAGE-F1 amplification and overexpression may contribute to increased tumor mutational burden through downregulation of MMS19. Given that MMS19 interacts with and possibly regulates several core DNA replication polymerases, it at first seems counter-intuitive to the notion that the MMS19 ubiquitin ligase MAGE-F1-NSE1 is amplified in cancer. However, MAGE-F1-NSE1 downregulation of MMS19 and the CIA pathway may in part foster tumorigenesis through promoting replication stress, leading to genomic instability, but not to a degree that impairs DNA replication. Thus, dampening of the CIA pathway by MAGE-F1 amplification may be an important factor in promoting genomic instability through replicative stress and downregulation of DNA repair pathways.
Extensive efforts have been made to develop immune checkpoint inhibitors, as cancer therapeutics and their clinical benefit have been unprecedented. However, precisely why some patients respond remarkably well and others more modestly has been of intensive study. Several studies have attributed these differences to the abundance of neoantigens presented to the competent immune cells after delivery of checkpoint inhibitors (Rizvi et al., 2015; Van Allen et al., 2015) . Given our findings that MAGE-F1 amplification is associated with increased mutational burden (increased neoantigens) in tumors, MAGE-F1 amplification could be a predictive biomarker for immune checkpoint inhibitors.
Evolution of MAGE-F1 Gene to Alter MMS19, CIA Pathway, and Iron Homeostasis Throughout the course of evolution, the MAGE-F1 gene appears to have undergone multiple insertion and deletion events to convert it from a protein-coding gene to a pseudogene. What is the cause for this rapid gain and loss across species? One plausible theory is that, because many immune-responserelated genes evolve quickly due to the nature of host-pathogen competition (Barreiro and Quintana-Murci, 2010) , MAGE-F1 may harbor roles in pathogen defense through altering cellular iron homeostasis. With these considerations, MAGE-F1 may be required in species that are exposed to certain extracellular bacterial pathogens. Alternatively, MAGE-F1 may have been actively selected against to protect against heavy exposure to intracellular viruses or to preserve a more efficient DNA repair process in species with high or long-term exposure to DNA damage over time. An interesting observation is that species with MAGE-F1 pseudogenes include those that have been noted to have relatively long lifespans with low observed cancer-associated mortality, such as elephants (lifespan: 60-80+ years; mortality from cancer: 5%; Abegglen et al., 2015; Lahdenper€ a et al., 2014) , whales (bowhead lifespan: $200 years; mortality from cancer: unknown but is presumed to be low due to their incredible lifespan; Keane et al., 2015) , and naked mole rats (lifespan: $32 years; mortality from cancer: only 2 natural cases ever recorded; Rodriguez et al., 2012) , whereas animals, such as cats and dogs, that possess the full-length coding MAGE-F1 appear to have incidences of cancers similar to humans (maximum lifespan recorded: 122 years; mortality from cancer: 11%-25%; Abegglen et al., 2015; Dong et al., 2016) . Although part of the underlying reason for cancer resistance in some species has been noted, such as abundance of TP53 copies in elephants (Abegglen et al., 2015) , it will be interesting to see whether the adaptive pseudogenization of MAGE-F1 and its effect on DNA repair capacity and iron homeostasis also contribute to lower incidence of cancer in these animals.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: EDTA, 1% Triton X-100, 1X protease inhibitor cocktail) for 30 minutes on ice. Lysates were dounced, spun down, and filtered through a 0.45 mm filter and incubated with anti-FLAG M2 beads (Sigma-Aldrich A2220) for 1 hour rotating at 4 C. Beads were then washed in 1X TBS 4 times and eluted for 5 fractions with elution buffer (150 pg/ml FLAG peptide in 1X TBS) at 4 C rotating, 30 minutes each. Eluted fractions with protein were then prepared with SDS sample buffer and run on SDS-PAGE gel until minimally resolved prior to submitting entire sample for mass spec analysis.
Co-immunoprecipitation and Immunoblotting 4x10
5 HeLa cells were plated in 6 cm dishes and transfected 24 hours later with Effectene (QIAGEN) according to manufacturers' protocol. 16 hr post-transfection, media was changed. 48 hr post-transfection, cells were washed and scraped in cold PBS, spun down, and resuspended in NP-40 lysis buffer (50 mM Tris-HCl pH 7.7, 150 mM NaCl, 0.5% NP-40 (v/v), 1 mM dithiothreitol (DTT), 1X protease inhibitor cocktail) for 45 minutes on ice prior to spinning down insoluble material. Soluble lysate was incubated with respective antibodies conjugated to Protein A beads (Bio-Rad) for 2 hours at 4 C while rotating. Beads were then washed in NP-40 lysis buffer 3-5 times and eluted with 2X sodium dodecyl sulfate (SDS) sample buffer.
For immunoblotting, samples prepared in SDS sample buffer were resolved on SDS-PAGE gels and then transferred to nitrocellulose membranes prior to blocking in TBST with 5% milk (w/v) or 5% bovine serum albumin (w/v) and probing with primary (as indicated above) and secondary antibodies (donkey anti-rabbit IgG, GE Healthcare, NA934V; sheep anti-mouse IgG, GE Healthcare, NA931V). Protein signal was visualized after addition of ECL detection reagent (GE Healthcare, RPN2209; GE Healthcare, RPN2236) as per manufacturer's instructions.
Purification of Recombinant Proteins
His-NSE1 and His-MAGE-F1-NSE1 complex were purified from 6 L LB cultures of BL21(DE3) or Rosetta 2(DE3) competent cells (EMD Millipore), respectively. Bacterial pellets were lysed in high salt lysis buffer (50 mM Tris-HCl pH 7.7, 500 mM NaCl, 100 mM ZnCl 2 , 10 mM imidazole), sonicated, and spun down at 2x10 4 RPM for 1 hour. Soluble lysate was filtered through a 0.45 mm filter and incubated with His Select Nickel Affinity Gel (Sigma, P6611) for 1 hour at 4 C rotating. Beads were then washed with high salt wash buffer (50 mM Tris-HCl pH 7.7, 500 mM NaCl, 100 mM ZnCl 2 , 20 mM imidazole) and eluted with 2 different elution buffers (50 mM Tris-HCl pH 7.7, 500 mM NaCl, 100 mM ZnCl 2 , 140 or 200 mM imidazole).
In Vitro Binding Assays 30 mg of either His-NSE1 or His-MAGE-F1-NSE1 complex were incubated with 8.75 ml TALON Metal Affinity Resin (Clontech) in TBST buffer (25 mM Tris pH 8.0, 2.7 mM KCl, 137 mM NaCl, 0.05% , and 10 mM 2-mercaptoethanol) for 1 hour vibrating at room temperature. Beads were then blocked with 5% non-fat milk (w/v) powder in TBST for 1 hour vibrating at room temperature. MYC-MMS19 was in vitro translated using TNT SP6 Quick In Vitro Transcription/Translation Kit (Promega) and added to the recombinant proteins in 5% milk (w/v) in TBST buffer vibrating for 1 hour. Beads were washed four times with TBST buffer prior to addition of 2X SDS sample buffer to elute.
Ubiquitination Assays 4x10
5 HeLa cells were plated in 6 cm dishes and transfected 24 hours later with Effectene according to manufacturers' protocol. 48 hr post-transfection, cells were treated for 4 hr with 10 mM MG132 before being collected in ice cold PBS. For anti-MYC-ubiquitin pulldowns, cells were resuspended in RIPA buffer (150 mM NaCl, 5 mM EDTA pH 8.0, 50 mM Tris-HCl pH 8.0, 1% NP-40 (v/v), 0.5% sodium deoxycholate (w/v), 0.1% SDS (w/v), 1mM DTT, and 1X protease inhibitor cocktail (Roche)) containing 10 mM PR-619 (Sigma), insoluble fraction removed by centrifugation, and soluble protein incubated with anti-MYC conjugated Protein A beads (Bio-Rad) for 2 hr at 4 C while rotating, washed, and eluted with 2X SDS sample buffer. For denaturing His-ubiquitin pull-down cell pellets were resuspended in denaturing lysis buffer (6M guanidinium-HCl, 100 mM Na 2 HPO 4 -NaH 2 PO 4 , 10 mM Tris-HCl pH 8.0, 5 mM imidazole, 10 mM 2-mercaptoethanol) and rotated for four hours at room temperature. Beads were spun down and washed successively with the following buffers for 5 minutes each at room temperature: 1) denaturing lysis buffer without imidazole 2) buffer A pH 8.0 (8 M urea, 100 mM Na 2 HPO 4 -NaH 2 PO 4 , 10 mM Tris-HCl pH 8.0, 10 mM 2-mercaptoethanol) 3) buffer A pH 6.3 with 0.2% Triton X-100 (v/v) (8M urea, 100 mM Na 2 HPO 4 -NaH 2 PO 4 , 10 mM Tris-HCl pH 6.3, 10 mM beta-mercaptoethanol, 0.2% Triton X-100 (v/v)) 4) buffer A pH 6.3 with 0.1% Triton X-100 (v/v) (8M urea, 100 mM Na 2 HPO 4 -NaH 2 PO 4 , 10 mM Tris-HCl pH 6.3, 10 mM beta-mercaptoethanol, 0.1% Triton X-100 (v/v)). Beads were then incubated with elution buffer (200 mM imidazole, 150 mM Tris-HCl pH 6.7, 30% glycerol (v/v), 5% SDS (w/v), 720 mM 2-mercaptoethanol) for 20 minutes at room temperature. Eluted fraction was then prepared with SDS sample buffer prior to running samples on SDS-PAGE gel.
Homologous Recombination Assay HR assays were performed essentially as described previously (Porteus and Baltimore, 2003; Potts et al., 2006) . Briefly, a 293 cell line (293/A658) expressing a GFP gene containing in-frame stop codons and a I-SceI recognition site (5 0 -TAGGATAACAGGGTAAT-3 0 ) at bp 327. The I-SceI/repair plasmid contained: an I-SceI expression cassette and a 2100 bp repair substrate that contains a truncated GFP gene (truncGFP) followed by an additional 1300 bp of 3 0 -homology to the mutated GFP genomic target. HR was measured by transfecting 293/A658 cells with the I-SceI/repair plasmid and the indicated plasmids or siRNA oligonucleotides. Cells were grown for three days and the percentage of GFP-positive cells was measured by flow cytometry and normalized to transfection efficiency controls.
55
Fe Incorporation Assay 55 Fe incorporation assays were performed as described previously (Stehling et al., 2004; Teichmann and Stremmel, 1990 FeCl 3 (Perkin Elmer) in 100 mM HCl, 63 mM nitrilotriacetic acid (NTA), and 20 mM HEPES pH to 6.0 with Tris followed by titration to pH 7.0 with 100 mM NaOH. After 55 Fe-NTA labeling, cells were washed in complete media, ice-cold PBS, and cell lysates were prepared in RIPA buffer (150 mM NaCl, 5 mM EDTA pH 8.0, 50 mM Tris-HCl pH 8.0, 1% NP-40 (v/v), 0.5% sodium deoxycholate (w/v), 0.1% SDS (w/v), 1mM DTT, and 1X protease inhibitor cocktail (Roche)). Fe-S proteins were immunoprecipitated by incubation of cell lysates with 5 mg antibody for 1 hour on ice followed by immunocomplex capture by addition of protein A agarose beads (Bio-Rad) for 1 hour rotating at 4 C. Beads were washed three times with RIPA buffer followed by scintillation counting. Data were normalized to protein lysate concentrations as determined by BCA analysis (Pierce).
Transferrin Uptake Assay
Transferrin uptake was performed as described previously (Stehling et al., 2008) . Briefly, 3.5x10
5 HeLa cells were plated in 6 cm dishes or 2x10
5 HeLa-Cas9 cells were plated in 6-well dishes and transfected 24 hours later with Effectene according to manufacturers' protocol. 72 hours after transfection cells were washed once in PBS followed by incubation with 0.1 mg/mL FITC-Transferrin (Invitrogen) in PBS for 1 hour at 37 C. Cells were then washed in PBS, cell lysates prepared in RIPA buffer, and FITC-Transferrin present in cell lysate was determined with a 96-well Enspire plate reader. Data were normalized to protein lysate concentrations as determined by BCA analysis (Pierce) and background signal from cells not treated with FITC-Transferrin.
Cell Viability Assays
To assess cell viability after siRNA knockdown, cells were reverse transfected with 20-35 nM siRNA and Lipofectamine RNAiMAX according to manufacturers' protocol and left to incubate for 72-120 hours prior to changing the media and adding MTT (Life Technologies) and incubating for 4 hours at 37 C in the dark. Media was then removed and DMSO was added to each well to solubilize crystals for 20 minutes. Plates were read at 540 nm on an Enspire plate reader. For MMS treatment, HeLa-Cas9 cells were plated at low density in 6-well plates and 16 hours later MMS was added at specified concentrations diluted in media. After 11 days fresh media was added and MTT (Life Technologies) was added according to manufactures' instructions. Cells were incubated for 4 hours at 37 C in the dark, media was then removed and DMSO was added to each well to solubilize crystals for 20 minutes. Plates were read at 540 nm on an Enspire plate reader. For UV treatment, 5x10
5 HeLa-Cas9 cells were plated in 6 cm plates. 16 hours later the cells were washed with PBS then directly irradiated using a Stratagene Stratalinker 2400 and immediately trypsinized and plated at low density in 6-well plates. Cells were then left to grow for 11 days and collected with MTT as described above.
